Premium
Ongoing remission after intensive All‐type chemotherapy in pediatric intestinal T‐cell lymphoma
Author(s) -
Friedrich Carsten,
Schrum Johanna,
Chott Andreas,
JankaSchaub Gritta,
Kabisch Hartmut
Publication year - 2010
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22330
Subject(s) - medicine , enteropathy , cd20 , cd30 , blood cancer , lymphoma , cd5 , cd8 , hemophagocytosis , chemotherapy , intraepithelial lymphocyte , cd3 , gene rearrangement , gastroenterology , oncology , immunology , disease , cancer , bone marrow , antigen , biochemistry , chemistry , pancytopenia , gene , immune system
A rare case of primary intestinal T‐cell lymphoma (ITL) of an 8‐year‐old boy is reported. Medium‐ to large‐sized tumor cells were βF1+, CD3+, CD8+. TIA‐1+, but CD4−, CD5−, CD30−, CD56−, CD20−, CD79a−, TdT−, consistent with an intraepithelial lymphocyte (IEL) origin. They showed monoclonal rearrangement of the T‐cell receptor γ‐chain and no evidence of EBV infection. No clinical, histologic, laboratory, or genetic evidence of celiac disease was detected. In adults, ITL is often associated with enteropathy and has a very poor outcome. Our patient remains in first remission 30 months after finishing the acute lymphoblastic leukemia protocol COALL‐07‐03 high risk standard. Pediatr Blood Cancer 2010;54:610–612. © 2009 Wiley‐Liss, Inc.